| Name | Title | Contact Details |
|---|
Scherago International is a Jersey City, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Current Health offers an enterprise care-at-home platform to enable healthcare organizations to deliver high-quality, patient-centric care at a lower cost. The company integrates patient-reported data with data from biosensors – including their own continuous monitoring wearable device – to provide healthcare organizations with actionable, real-time insights into the patient’s condition. Leveraging clinical algorithms that can be tailored to the individual patient, Current Health identifies when a patient needs clinical attention, allowing organizations to manage patient care remotely or coordinate in-home care via our integrated service partners. The Current Health platform brings together telehealth capabilities, patient engagement tools, and in-home connectivity to provide a single solution to manage all care in the home.
Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage. Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions. These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization. In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.
MEDNET USA is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cottage Glen Assisted Living is a Tooele, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.